赛特金斯公司2025年季度报告

CYTOKINETICS, INCORPORATED Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and CYTOKINETICS, INCORPORATEDTABLE OFCONTENTS FOR FORM 10-QFOR THE THREE MONTHS ENDED MARCH 31, 2025 Glossary of Terms PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders’ DeficitCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial Statements Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures PART II. OTHER INFORMATIONItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. ExhibitsSIGNATURES GLOSSARY OF TERMS Unless the context requires otherwise, references to “Cytokinetics,” “the Company,” “we,” “us” or “our” in this QuarterlyReport on Form 10-Q refer to Cytokinetics, Incorporated and its subsidiaries. References to “Notes” in this Form 10-Q are to theNotes to the Condensed Consolidated Financial Statements in this Form 10-Q. We also have used other specific terms in this Form This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates.These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussionherein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differinginterpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new CYTOKINETICS and our C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.Other service marks, trademarks and trade names referred to in this report are the property of their respective owners. The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts,or any third-party website, is not incorporated by reference into this Form 10-Q. CYTOKINETICS, INCORPORATEDCONDENSED CONSOLIDATED BALANCE SHEETS CYTOKINETICS, INCORPORATEDNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1 — Organization and Significant Accounting Policies Cytokinetics, Incorporated was incorporated under the laws of the state of Delaware on August 5, 1997. We are a late-stagebiopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle Our financial statements contemplate the conduct of our operations in the normal course of business. We have incurred anaccumulated deficit of approximately$2.9billionsince inception and there can be no assurance that we will attain profitability. Wehad a net loss of$161.4millionand net cash used in operations of$131.6millionfor the three months ended March 31, 2025. We are subject to risks common to late-stage biopharmaceutical companies including, but not limited to, development ofnew drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund our future plans.Our liquidity will be impaired if sufficient additional capital is not available on terms acceptable to us. To date, we have fundedoperations primarily through sales of our common stock, contract payments under our collaboration agreements, sales of futurerevenues and royalties, debt financing arrangements, and interest income. Until we achieve profitable operations, we intend tocontinue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt Our success is dependent on our ability to obtain additional capital by entering into financings or new strategiccollaborations, and ultimately on our and our collaborators’ ability to successfully develop and market one or more of our drugcandidate